Crown Bioscience, Inc., a Santa Clara California-based global drug discovery and development service company, raised $26.55m in Series D funding.
The round was led by Lilly Asia Ventures Fund II L.P.
The company intends to use the funds for expansion plans for their platforms.
Founded in 2006 and led by Dr Jean-Pierre Wery, President, Crown Bioscience develops platform technologies in oncology and metabolic diseases, which allow drug development companies to make better-informed decisions on clinical drug candidates.
The investment, which closed on 25th April, will provide the company with the ability to expand its technologies, including the HuPrime®, HuKemia®, HuBase™, HuMark™, HuTrial™ and HuSignature™ platforms.
The company has operations in China (Beijing and Jiangsu Taicang), United Kingdom (Precos, Ltd. In Nottingham) and the USA (NC) with business offices in Boston, Princeton, RTP, Phoenix, Milan and Shanghai.
FinSMEs
25/05/2014
Related News
04/05/2011: Crown Bioscience Closes US$28.8M Series C Financing